Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FYU-981 in hyperuricemic outpatients
NCT03375632Phase 1Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dotinurad in hyperuricemia and gout (2 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoint: Amount of uric acid excreted in urine at 14 weeks. Started Jan 2018; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT03375632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375632.